Daylife Select
A point & click tool to create dynamic content portals. Learn More »
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
MONDAY, Dec. 7 (HealthDay News) A new blood thinner called dabigatran etexilate may be just as effective in preventing dangerous venous clots as an old standby, warfarin, but much easier for doctors and patients to manage, a new study finds. Full Article at Forbes
BURLINGTON, ON, Dec. 6 /CNW/ - Results from the landmark RE-COVER(TM) study were presented today at the American Society of Hematology Annual Meeting and published online in the New England Journal of Medicine. Full Article at Drugs.com
In this photo taken on Thursday, Dec. 4, 2008, San Antonio Spurs forward Fabricio Oberto, of Argentina, takes the floor before facing the Denver Nuggets in the first quarter of an NBA basketball game in Denver. View Photo »
This European approval is good news for doctors and patients since atrial fibrillation affects about 4.5 million people in Europe and represents one-third of hospitalizations for arrhythmia in the European Union
December 6, 2009 9:00 AM EST -- Primary prevention of VTE in patients undergoing elective total hip and knee replacement surgeries (10,11,14) -- Treatment of acute VTE (4) -- Secondary prevention of VTE (5,6) -- Prevention of atherothrombotic... Full Article at Street Insider
Editor's Choice Main Category: Heart Disease Also Included In: Cardiovascular / Cardiology; Hypertension Article Date: 04 Dec 2009 - 0:00 PST email to a friend printer friendly view / write opinions rate article Beta-blockers, also known as... Full Article at Medical News Today
Dear Dr. Gott: I am an active, healthy 72-year-old female concerned about a recent diagnosis of atrial fibrillation. I have had approximately six episodes over the past seven months. Full Article at Monterey County Herald
This is a Dec. 4, 2008 file photo showing San Antonio Spurs forward Fabricio Oberto, of Argentina, before facing the Denver Nuggets in an NBA basketball game in Denver. Oberto will miss San Antonio's next two games because of an irregular heartbeat. View Photo »
The approval of Multaq(R) in the European Union is important news for atrial fibrillation patients who will now have access to a new treatment approach
By PETER GOTT, M.D. Newspaper Enterprise Association Published: 12/4/2009 2:19 AM Last Modified: 12/4/2009 2:19 AM Dear Dr. Gott: I am an active, healthy 72-year-old female concerned about a recent diagnosis of atrial fibrillation. Full Article at Tulsa World
QI am an active, healthy 72-year-old female concerned about a recent diagnosis of atrial fibrillation. I have had approximately six episodes over the past seven months. Full Article at GoErie.com
There are no results for this module. Edit this module to change the search term used to query Wikipedia
In this photo taken on Thursday, Dec. 4, 2008, San Antonio Spurs forward Fabricio Oberto, of Argentina, takes the floor before facing the Denver Nuggets in the first quarter of an NBA basketball game in Denver.
View Photo »This is a Dec. 4, 2008 file photo showing San Antonio Spurs forward Fabricio Oberto, of Argentina, before facing the Denver Nuggets in an NBA basketball game in Denver. Oberto will miss San Antonio's next two games because of an irregular heartbeat.
View Photo »This is a Dec. 4, 2008 file photo showing San Antonio Spurs forward Fabricio Oberto, of Argentina, before facing the Denver Nuggets in an NBA basketball game in Denver. Oberto will miss San Antonio's next two games because of an irregular heartbeat.
View Photo »This European approval is good news for doctors and patients since atrial fibrillation affects about 4.5 million people in Europe and represents one-third of hospitalizations for arrhythmia in the European Union
The approval of Multaq(R) in the European Union is important news for atrial fibrillation patients who will now have access to a new treatment approach
Globally, we've seen the development of a number of advanced devices that deliver more effective treatment of atrial fibrillation ... New electrophysiology catheters in particular have allowed physicians to target the unique physiological demands of atrial fibrillation and will drive procedural growth t...
Globally, we've seen the development of a number of advanced devices that deliver more effective treatment of atrial fibrillation ... New electrophysiology catheters in particular have allowed physicians to target the unique physiological demands of atrial fibrillation and will drive procedural growth t...
It is a tremendous privilege to receive this challenge grant from the National Heart, Lung and Blood Institute ... We now have the opportunity to make major headway in the prevention of atrial fibrillation.
Diabetes has long been recognized as a risk factor for atrial fibrillation
Atrial fibrillation was more common in men, but the incidence in women with diabetes was almost identical to that of men without diabetes ... That’s the take-home message.
For women with atrial fibrillation, these gender differences should always be kept in mind to help prevent strokes and heart failure and improve their quality of life
We reviewed past studies addressing gender differences in atrial fibrillation over a 20 year period in order to pinpoint the gender differences for women versus men with atrial fibrillation. As a result, we were able to determine the most rational, safe and effective gender-specific approach to therapy ...
There are no results for this module. Edit the module to change the search term used to query Twitter.
